Beta Bionic, Inc. (BBNX)

Beta Bionic Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Revenue	53.03	12	0.18
Revenue Growth (YoY)	-	6601.12%	-
Cost of Revenue	-	5.69	-
Gross Profit	29.26	6.31	0.18
Selling, General & Admin	-	24.22	34.6
Research & Development	-	17.94	31.43
Operating Expenses	-	42.16	66.02
Operating Income	-40.58	-35.85	-65.84
Interest Expense / Income	-4.15	-1.71	-0.18
Other Expense / Income	19.07	9.96	-0.91
Pretax Income	-55.5	-44.1	-64.75
Net Income	-55.5	-44.1	-64.75
Free Cash Flow	-43.49	-32.85	-60.98
Gross Margin	55.17%	52.59%	100.00%
Operating Margin	-76.52%	-298.87%	-36784.36%
Profit Margin	-104.64%	-367.64%	-36173.74%
Free Cash Flow Margin	-82.00%	-273.84%	-34067.04%
EBITDA	-57.35	-43.72	-62.85
EBITDA Margin	-108.14%	-364.46%	-35109.50%
Depreciation & Amortization	2.3	2.09	2.09
EBIT	-59.65	-45.81	-64.93
EBIT Margin	-112.47%	-381.89%	-36275.42%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).